

# Enrolled 126% of the Expected Goal in Phase 3 Pneumococcal Vaccine Trial

## Our Objectives

DelRicht Research was selected as a participating site network for a Phase 3 Pneumococcal Vaccine trial targeting healthy male and female adults ≥18 years of age without a history of IPD, pneumococcal pneumonia, or prior receipt of any pneumococcal vaccine.

- **Total Enrollment Goal:** 4000 patients across 30 sites
- **DelRicht Enrollment:** 267 patients across 2 sites
- **Patient Population:** Adults ≥18 years of age
- **Enrollment Period:** December 2025 – March 2026

## Key Trial Challenges

- 1 Pneumococcal-Naïve Recruitment:** Strict eligibility criteria requiring **no prior IPD, pneumonia diagnosis, or pneumococcal vaccination**, combined with the need for verification via records/registries, significantly narrowed the eligible pool, particularly in the 65+ population.
- 2 eDiary Management:** A **7-day eDiary with strict 24-hour completion windows** required intensive oversight. Email-based diary access created usability barriers, particularly among older populations with limited email access or digital literacy.

## Solutions Implemented

- 1 Optimized for Recruitment:** Multi-channel outreach and centralized call center guides patients from interest to enrollment. With **~10 leads required per qualified pre-screen**, our team scaled capacity to be able to **contact a high volume of patients, all within 10 minutes** of indicating interest, driving high conversion to meet enrollment goals.
- 2 Facilitated eDiary Compliance:** Enhanced diary compliance through a comprehensive approach combining **proactive daily monitoring and rapid follow-up with hands-on patient education** (email setup, navigation guidance, and personalized reminders), such as flagging diary emails at randomization to minimize missed entries.

## Our Results

DelRicht's two sites **enrolled 337 participants**, achieving **126% of the study target**. Sites were activated prior to enrollment and able to **screen the same day as enrollment opening**. DelRicht demonstrated seamless sponsor and CRO coordination, and the ability to deliver high-quality, reliable data for complex, high-priority studies.

 **337** Patients Enrolled

 **126%** of the Expected Enrollment Goal

## The Study


**Client:** Mid-Size Biotech

**Trial:** Phase 3 Pneumococcal Vaccine Trail

## Participating PIs



**Dr. Sean Kerby**  
*Gulfport, MS*  
Gulfport Memorial



**Dr. Patrick Dennis**  
*New Orleans, LA*  
Touro Medical Center



*Dr. Sean Kerby  
Gulfport, MS*



*Dr. Patrick Dennis  
New Orleans, LA*